Relation Therapeutics Limited

Founded in 2019 and based in London, UK, Relation Therapeutics Limited operates as a biotechnology research platform that uses machine learning to discover and develop biological therapeutics. In December 2025, Relation Therapeutics Limited raised USD 26 million in venture funding co-led by DCVC, Nventures, and Magnetic. The company's work includes human genetics, human tissue profiling, functional genomics, ActiveGraph ML, and clinical translation. The firm provides a platform that uses the power of ActiveGraph ML to understand the vast number of combinatorial functional relationships between genes, proteins, and drugs.

Relation's technology generates genomic data that provides direct insights into critical biological relationships and is fed directly into the company's machine learning systems. The company's platform then requests new experiments in order to improve its predictive ability, allowing it to navigate an otherwise intractable combinatorial space. The company will use the December 2025 funding to build out its lab-in-the-loop setup, gather human tissue data, and speed up AI-based research to identify new drug targets for atopic diseases.